Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
147 Leser
Artikel bewerten:
(0)

Zecotek Signs Joint Collaboration Agreement with Intellectual Ventures

VANCOUVER, June 28, 2013 /PRNewswire/ - Zecotek Photonics Inc. (TSX-V: ZMS; OTCPK: ZMSPF, Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it has entered into a joint collaboration agreement with Intellectual Ventures (IV®) of Bellevue, Washington. The two companies will collaborate on intellectual property strategy, including the sourcing, development, and monetization of new inventions related to photonics. IV is one of the largest owners of U.S. patents and works closely with inventors to develop and protect intellectual property.

"The agreement with Intellectual Ventures marks another important step for Zecotek in the effort to build and protect its valuable patent portfolio of over 50 patents," said Dr. A. Faouzi Zerrouk, Founder and CEO of Zecotek. "The collaboration with Intellectual Ventures aims to enhance the innovation pipelines available to Zecotek, further strengthen our intellectual property portfolio, and align us with the world's leading specialty invention company."

"Intellectual Ventures is proud to collaborate with and offer consultation to Zecotek, a cutting-edge photonics technology company," said Chris Alliegro, Executive Vice President and Managing Director, Invention Development Fund at Intellectual Ventures. "The inventors at Zecotek are truly world-class, and through this collaboration we will create a strong portfolio of photonics related inventions and patents that bring further innovation to important products such as PET-MRI imaging systems used in medical, and industrial systems."

The agreement also provides Zecotek with the opportunity to license IP and technologies from the IV Invention Development Fund's own portfolio of photonics related inventions and patents created with its network of more than 4,000 inventors - including individual inventors and inventors from government labs, research institutions, corporations and universities. As part of the terms of the agreement, Intellectual Ventures will have the first right of refusal to purchase any inventions or patents Zecotek may choose to divest.

Zecotek intends to issue shares for services to Intellectual Ventures in exchange for the provisions included in the joint collaboration agreement. The provisions of the agreement and the issuance of shares for service are subject to approval by the TSXV and to compliance with all applicable regulatory requirements.

About Intellectual Ventures
Founded in 2000, Intellectual Ventures (IV) is the global leader in the business of invention. IV collaborates with leading inventors, partners with pioneering companies, and invests both expertise and capital in the process of invention. IV's mission is to energize and streamline an invention economy that will drive innovation around the world. For more information, please visit www.intellectualventures.com, follow IV on Twitter at @IVinvents and "like" IV on Facebook at facebook.com/intven.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as the European Organization for Nuclear Research (Switzerland), BeijingOpto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit www.zecotek.com, follow @zecotek on Twitter and "like" us in Facebook at www.facebook.com/zecotek.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

SOURCE Zecotek Photonics Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.